Novartis Multidisciplinary Meeting - Heart Failure and Rheumatology

COLLECTION STATEMENT: Your personal information will be processed in accordance with the Novartis Privacy Policy at https://www.novartis.com.au/privacy-policy. Read more

Your personal information will be processed in accordance with the Novartis Privacy Policy at https://www.novartis.com.au/privacy-policy. Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.
Novartis has engaged third party service providers, including AddEvent, to administer this activity including processing your personal information.
You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy.
Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting.In line with Medicines Australia Code of Conduct, hospitality, travel or other expenses of any guest, family, or traveling companion will not be paid for or subsidised by Novartis.